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Introduction
Maintaining serum phosphate within a fairly narrow physiological range is critical for proper ener-
gy metabolism and prevents mineralization of  soft tissues. Control of  phosphate handling occurs 
through dietary absorption in the intestine, through renal reabsorption, and via long-term storage 
in the skeleton (1). Fibroblast growth factor-23 (FGF23) is a bone-produced hormone involved in 
maintaining phosphate balance through control of  renal phosphate reabsorption and 1,25(OH)2 
vitamin D (1,25D) synthesis (2). After its release from osteoblasts/osteocytes in humans and rodent 
models of  situations of  hyperphosphatemia (3–5) or increased 1,25D (6), FGF23 binds to its core-
ceptor α-Klotho and an FGF receptor (FGFR) in the kidney (7, 8). FGF23 signaling reduces expres-
sion of  the renal proximal tubule sodium-phosphate cotransporters NPT2a and NPT2c, increasing 
phosphate excretion (9, 10). To control 1,25D, the actions of  FGF23 downregulation of  renal vita-
min D 1α-hydroxylase (CYP27b1), and increased expression of  vitamin D 24-hydroxylase (CYP24a1), 
lead to a decrease in circulating 1,25D (9). Parathyroid hormone (PTH) has the same effect as 
FGF23 on tubular phosphate reabsorption, but converse effects on 1,25D production (11). Bone 
FGF23 mRNA expression and circulating concentrations are influenced by multiple factors includ-
ing systemic changes in phosphate (5), 1,25D (6, 12), PTH (13), iron handling (14), inflammation 
(15, 16), as well as local factors including FGF/FGFR1 bioactivity (17, 18), and soluble α-Klotho 
overexpression (19, 20). The critical role of  FGF23 in phosphate balance is underscored by the fact 
that excess FGF23 production causes disorders of  hypophosphatemia due to heterogeneous genetic 
defects (21–27). In the converse situation, reduced secretion of  bioactive FGF23 results in hyper-
phosphatemic familial tumoral calcinosis (hfTC) (28–32).
The phosphaturic hormone FGF23 is elevated in chronic kidney disease (CKD). The risk of premature 
death is substantially higher in the CKD patient population, with cardiovascular disease (CVD) 
as the leading mortality cause at all stages of CKD. Elevated FGF23 in CKD has been associated 
with increased odds for all-cause mortality; however, whether FGF23 is associated with positive 
adaptation in CKD is unknown. To test the role of FGF23 in CKD phenotypes, a late osteoblast/
osteocyte conditional flox-Fgf23 mouse (Fgf23fl/fl/Dmp1-Cre+/–) was placed on an adenine-
containing diet to induce CKD. Serum analysis showed casein-fed Cre+ mice had significantly higher 
serum phosphate and blood urea nitrogen (BUN) versus casein diet and Cre– genotype controls. 
Adenine significantly induced serum intact FGF23 in the Cre– mice over casein-fed mice, whereas 
Cre+ mice on adenine had 90% reduction in serum intact FGF23 and C-terminal FGF23 as well 
as bone Fgf23 mRNA. Parathyroid hormone was significantly elevated in mice fed adenine diet 
regardless of genotype, which significantly enhanced midshaft cortical porosity. Echocardiographs 
of the adenine-fed Cre+ hearts revealed profound aortic calcification and cardiac hypertrophy 
versus diet and genotype controls. Thus, these studies demonstrate that increased bone FGF23, 
although associated with poor outcomes in CKD, is necessary to protect against the cardio-renal 
consequences of elevated tissue phosphate.
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In the setting of  chronic kidney disease (CKD), serum phosphate levels are largely within normal ranges 
until end-stage disease (33). With kidney failure, the expression of  α-Klotho progressively falls, leading to 
a situation of  FGF23 resistance (34); this in turn, leads to higher circulating FGF23 to attempt to maintain 
phosphate balance. The physiological price for relatively normal serum phosphate in the setting of  CKD is a 
reduction in 1,25D synthesis, leading to reduced calcium absorption, hypocalcemia, and hyperparathyroid-
ism (35). Although the mechanisms remain unclear, FGF23 is independently associated with a significantly 
increased odds ratio for CKD patient mortality (36), predicts responses to calcitriol therapy (37), and is 
linked to development of  left ventricular hypertrophy (LVH) (38, 39). Cardiac hypertrophy is a multifactorial 
and important mechanism of  cardiovascular disease (CVD) in CKD that contributes to diastolic dysfunc-
tion, congestive heart failure, and sudden death. Compared with a prevalence of  less than 20% in the general 
population, cardiac hypertrophy affects up to 70% of  patients during moderate CKD and approaches 90% 
of  patients on dialysis (40). Although elevated FGF23 is associated with cardiac hypertrophy, the extent of  
soft tissue calcifications (41), anemia (42), tissue hypoxia (43), inflammation (44), and paracrine/autocrine 
factors such as Wnt-related proteins and other FGFs (45, 46), which likely play significant roles, remains to 
be determined. Thus, the complete functions of  FGF23 in maintaining mineral homeostasis, as well as its 
potential crosstalk with other metabolic systems in CKD, are not fully understood.
A mouse harboring a conditional Fgf23 allele (flox-Fgf23) was developed to test targeted restriction of  
FGF23 expression and function in vivo. We previously showed that osteoblast/osteocyte–specific flox-
Fgf23 recombination using Dmp1-Cre suppressed circulating bioactive, intact FGF23 (iFGF23) in mice 
with normal renal function (47). Importantly, this animal was resistant to increasing FGF23 following 
high-phosphate dietary challenge (47). Additionally, the osteoblast/osteocyte recombined flox-Fgf23 allele 
rescued the inappropriately elevated FGF23, as well as the biochemical and skeletal disease in the Hyp 
mouse model of  X-linked hypophosphatemia (XLH) (47). Herein, we showed through Cre-mediated tar-
geting that elevated FGF23 is necessary to avoid systemic effects typically associated with hyperphospha-
temia during CKD, providing almost complete protection against vascular calcification and subsequent 
cardiac hypertrophy.
Results
Mineral metabolism during CKD. To determine the role of  FGF23 in CKD progression and manifestations, 
conditional deletion of  a flox-Fgf23 allele was targeted to osteoblasts/osteocytes by breeding to a Dmp1-
Cre–transgenic line (48) to create flox-Fgf23/Dmp1-Cre+/– mice. Adenine diet was used to induce CKD (51), 
and female mice were studied to permit an extended CKD time course for study, as males are known to 
be far more sensitive to adenine (52). From weaning to 8 weeks of  age, the mice were fed a normal rodent 
chow; mice were then switched to either a control casein-containing diet or a 0.2% adenine–containing 
diet for 4 or 8 additional weeks. In the 8-week treatment groups, interim bleeds were taken at 4 weeks. To 
test hormonal responses during CKD, serum intact FGF23 (iFGF23) concentrations were measured. At 4 
weeks on the experimental diets, serum bioactive iFGF23 concentrations were significantly elevated in the 
flox-Fgf23/Dmp1-Cre– mice fed adenine (Figure 1A). However, the flox-Fgf23/Dmp1-Cre+ mice had signifi-
cantly lower serum iFGF23 than the flox-Fgf23/Dmp1-Cre– mice, which remained virtually unchanged at 
the 8-week time point (Figure 1A). Flox-Fgf23/Dmp1-Cre+ mice receiving adenine had significantly elevat-
ed serum iFGF23 over flox-Fgf23/Dmp1-Cre+ and flox-Fgf23/Dmp1-Cre– mice receiving control diet (Figure 
1A). Serum iFGF23 was not different in the control-diet-fed mice (Figure 1A). Consistent with the marked 
reduction in serum FGF23, cortical bone Fgf23 mRNA levels were significantly lower (~90%; P < 0.01) 
in the flox-Fgf23/Dmp1-Cre+ mice compared with the flox-Fgf23/Dmp1-Cre– mice fed adenine at 4 weeks 
(Figure 1B). At 8 weeks on diet, the flox-Fgf23/Dmp1-Cre+ adenine-fed mice maintained significantly lower 
Fgf23 mRNA compared with flox-Fgf23/Dmp1-Cre– mice (Figure 1B).
Biochemical manifestations of  lower FGF23 during CKD. Upon analysis of  serum biochemistries, phos-
phate concentrations were found to be similar between casein-fed flox-Fgf23/Dmp1-Cre– and /Dmp1-Cre+ 
mice at 4 weeks, but a significant difference between the 2 groups at 8 weeks, with flox-Fgf23/Dmp1-Cre+ 
mice having increased concentrations (Figure 1C). When receiving adenine diet, the flox-Fgf23/D-
mp1-Cre+ mice had a significant increase in serum phosphate versus flox-Fgf23/Dmp1-Cre–littermates 
at both time points (Figure 1C); serum calcium levels were not different across all genotypes and diets 
(Table 1). Blood urea nitrogen (BUN) was monitored for decline in renal function, and as expected, 
adenine diet was associated with a significantly increased BUN, but concentrations were further elevated 
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in the flox-Fgf23/Dmp1-Cre+ mice at the 8-week time point (Figure 1D). Serum creatinine levels paral-
leled BUN (Table 1). Serum alkaline phosphatase was significantly reduced in the flox-Fgf23/Dmp1-Cre+ 
compared with the flox-Fgf23/Dmp1-Cre–littermates fed either diet (Table 1), but after 8 weeks was sig-
nificantly elevated in the adenine-fed flox-Fgf23/Dmp1-Cre+ mice compared with controls. This pattern 
trended similarly in the flox-Fgf23/Dmp1-Cre– mice between diets but did not reach significance (Table 
1). Similar to previous reports with adenine administration, serum total iron was significantly reduced in 
the adenine-fed mice compared with the casein controls after 8 weeks of  diet administration. No differ-
ences were observed in iron levels between genotypes fed either the casein or adenine diet.
Skeletal and renal phenotypes with CKD and reduced FGF23 expression. Upon analysis of other key hormones 
involved in the CKD pathogenesis, the adenine diet was noted to induce hyperparathyroidism. Regardless of  
genotype, all mice receiving adenine had significantly higher serum PTH compared with the casein control 
group at both the 4- and 8-week time points (Figure 1E). As chronically elevated PTH concentrations are 
known to increase osteoclast activity, femora underwent micro–computed tomography (μCT) analysis. Mice 
fed the adenine diet showed increased porosity, and when quantified showed that femoral cortical porosity was 
significantly higher than casein by even 4 weeks of diet administration (Supplemental Figure 1A; supplemen-
tal material available online with this article; https://doi.org/10.1172/jci.insight.123817DS1). Furthermore, 
there were no differences observed between genotypes (Supplemental Figure 1B). The level of cortical porosity 
was maintained after 8 weeks of adenine diet administration, with no differences observed between genotypes.
FGF23 is typically a potent suppressor of  the renal vitamin D 1α-hydroxylase (Cyp27b1) (10), where-
as PTH has the converse effect on this enzyme (53). Consistent with elevated PTH, renal expression of  
Figure 1. Biochemical and molecular phenotypes of flox-Fgf23 mice during CKD. (A) Flox-Fgf23/Dmp1-Cre mice were placed on casein control or 0.2% 
adenine diet for 8 weeks. By 4 weeks on diet, serum intact FGF23 levels were significantly elevated in the mice fed adenine diet, yet the levels in flox-Fg-
f23/Dmp1-Cre+ mice were significantly lower than those in the flox-Fgf23/Dmp1-Cre– mice, which continued at the 8-week time point. (B) Bone Fgf23 
mRNA levels rose in the flox-Fgf23/Dmp1-Cre– mice fed adenine at 4 weeks on diet versus casein control. At 8 weeks on diet, the flox-Fgf23/Dmp1-Cre+ 
adenine-fed mice had significantly lower Fgf23 mRNA compared with flox-Fgf23/Dmp1-Cre–. (C) Serum phosphate levels were found to be similar between 
flox-Fgf23/Dmp1-Cre– and flox-Fgf23/Dmp1-Cre+ mice at 4 weeks on casein, with an increase in the flox-Fgf23/Dmp1-Cre+ mice at 8 weeks. On adenine 
diet, the Cre+ mice had a significant increase versus flox-Fgf23/Dmp1-Cre– littermates on the adenine diet at both time points. (D) Blood urea nitrogen 
(BUN) levels were measured to monitor renal function. As expected, adenine diet increased these levels, but were further elevated in the Cre+ mice on ade-
nine at the 8-week time point. (E) Serum analysis also showed that the adenine diet model induced hyperparathyroidism. All mice receiving adenine had 
a significant increase in serum PTH compared with the casein control group, even at the 4-week time point. There was no difference between genotypes 
and there was no further increase at the 8-week time point in the adenine-fed mice (n = 4–6 per group). *P < 0.05, **P < 0.01 versus casein diet within the 
same genotype; ‡P < 0.05 versus Cre– on the same diet.
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Cyp27b1 mRNA was increased in all mice fed the adenine diet to a similar extent, despite the highly ele-
vated levels of  FGF23 in the flox-Fgf23/Dmp1-Cre– adenine-fed groups (Figure 2A). The coreceptor for 
FGF23, α-Klotho, is found to be reduced during CKD. Indeed, Klotho mRNA levels decreased with ade-
nine diet administration by 4 weeks in both genotypes (Figure 2B). After 8 weeks of  diet administration, 
Klotho mRNA showed no further decrease in the adenine-fed groups and no differences between genotypes. 
Over the course of  renal damage, fibrotic tissue accumulates, which can be measured by the level of  type 
1 collagen (Col1a1; Figure 2C). Renal mRNA expression of  Col1a1 is dramatically increased with adenine 
diet administration by 4 weeks, indicative of  renal damage and in line with serum creatinine and BUN 
levels. However, Col1a1 levels were not further enhanced with an additional 4 weeks of  diet consumption. 
Additionally, Col1a1 mRNA levels measured in the adenine-fed flox-Fgf23/Dmp1-Cre+ group were similar 
to the adenine-fed flox-Fgf23/Dmp1-Cre– mice (Figure 2C). Histological analysis of  the kidney demonstrat-
ed increased fibrosis and cellular infiltrates within the adenine-fed mice (Figure 2D). Von Kossa staining 
elucidated mineral deposition, which occurred in all flox-Fgf23/Dmp1-Cre+ adenine-fed mice and 20% of  
the flox-Fgf23/Dmp1-Cre– adenine-fed animals (Table 2). Expression levels for markers of  inflammation 
including tumor necrosis factor α (Tnfa), C-reactive protein (Crp), and interleukin-6 (Il6) were all found 
significantly elevated in kidneys from the adenine-fed groups compared with the casein-fed mice (Figure 
2, E–G). Interestingly, Crp and Il6 mRNA expression was further enhanced in the flox-Fgf23/Dmp1-Cre+ 
adenine-fed mice compared with the adenine-fed flox-Fgf23/Dmp1-Cre– mice (Figure 2, F and G). Consis-
tent with mineral accumulation, expression levels of  runt-related transcription factor (Runx2) were elevated 
in all animals receiving adenine; however, no differences between genotypes were observed despite higher 
prevalence of  mineral content within the adenine-fed flox-Fgf23/Dmp1-Cre+ kidneys.
Cardiac morphology with CKD in the context of  blunted FGF23 expression. Cardiac hypertrophy in CKD is a 
multifactorial pathogenesis involving tissue calcification (54), local growth factors (55), as well as a direct role of  
FGF23 (38). To monitor heart properties during CKD onset, echocardiograph images were collected from the 
mice prior to the 8-week time point. Representative long-axis images collected in B-mode show the aorta down 
to the apex of the open left ventricle (Figure 2A). Whereas no gross changes were observed between the geno-
types at baseline, the flox-Fgf23/Dmp1-Cre+ mice fed adenine showed thicker aortic walls with calcification (Fig-
ure 3A). Additionally, ejection fraction and fractional shortening were significantly increased in the adenine-fed 
flox-Fgf23/Dmp1-Cre+ mice (Table 3). H&E staining of representative hearts from the adenine-fed group showed 
pronounced hypertrophy of the left ventricle in the flox-Fgf23/Dmp1-Cre+ mice fed adenine compared with 
flox-Fgf23/Dmp1-Cre– mice (Figure 3B). These mice also contained calcification in the heart tissue; however, 
they displayed variable locations of accumulation (Supplemental Figure 2). Hypertrophy was also found to 
occur at the cellular level. Cardiomyocyte cell area increased in mice fed adenine compared with the casein-fed 
mice and was further increased in the adenine-fed flox-Fgf23/Dmp1-Cre+ mice (Figure 3C). Thus, high FGF23 
over the time-course studies was associated with partial protection from cardiac hypertrophy in this model.
Discussion
In the current work, we found that providing an adenine-containing diet to mice induces renal disease and 
potently increases FGF23 and PTH, modeling the endocrine profile of  patients with CKD. Although target-
ed deletion of  Fgf23 from osteoblast/osteocytes reduced FGF23 protein and bone mRNA levels 90%, this 
reduction did not inhibit the incidence of  hyperparathyroidism, nor did it prevent the resulting increase in 
Table 1. Serum biochemical analysis
4 week 8 week
Casein Cre– Casein Cre+ Adenine Cre– Adenine Cre+ Casein Cre– Casein Cre+ Adenine Cre– Adenine Cre+
Calcium (mg/dl) 9.58 + 0.28 9.96 + 0.45 8.85 + 0.7 9.15 + 0.4 11.98 + 1.72 11.53 + 0.49 10.85 + 0.32 11.91 + 0.79
Total Iron (μg/dl) 127.16 + 34 133.75 + 31 84.81 + 13 91.03 + 2.5
Total Iron (μmol/l) 42.38 + 1.5 35.4 + 3.5 20.96 + 1.4A 22.50 + 1.4A
Alk Phos (U/l) 181 + 14 99.75 + 10B 139.4 + 17 108.75 + 13 131.25 + 11 83.40 + 7.8C 150.00 + 5.9 125.25 + 6.9A
Creatinine (mg/dl) 0.37 + 0.04 0.31 + 0.04 0.55 + 0.08 0.64 + 0.07B 0.41 + 0.08 0.45 + 0.03 0.79 + 0.02A 0.94 + 0.05A
Data presented as mean + SD. n = 4–6 per group. AP < 0.01 vs. casein diet, same genotype. BP < 0.05, CP < 0.01 vs. Cre–, same diet.
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Figure 2. Renal phenotypes under clamped FGF23. (A) Consistent with high PTH, renal expression of 1α-hydroxylase (CYP27b1) was increased in all mice fed 
the adenine diet and despite the highly elevated levels of FGF23 in the flox-Fgf23/Dmp1-Cre– adenine-fed group. (B) Renal Klotho mRNA levels were reduced in 
the adenine-fed mice compared with the casein-fed groups. (C) Fibrosis marker Col1a1 was significantly upregulated with adenine diet administration compared 
with casein. These levels were maintained by 8 weeks on diet with no differences between genotypes. (D) H&E and Masson’s trichrome staining of the kidney 
tissue showed increased cell infiltration and fibrosis within the adenine-fed mice. Mineral accumulation detected by von Kossa staining was most pronounced 
in the adenine-fed flox-Fgf23/Dmp1-Cre+ group. Scale bars: 500 μm and 100 μm (insets). (E) Tnfa mRNA levels were found to be increased in both genotypes fed 
adenine compared with casein. Expression of inflammation markers Crp (F) and Il6 (G) mRNA was significantly induced in adenine-fed mice, but was also found 
at significantly higher levels in the adenine-fed flox-Fgf23/Dmp1-Cre+ mice compared with the adenine-fed flox-Fgf23/Dmp1-Cre– group. (H) Runx2 mRNA 
expression, related to mineral deposition, was increased in both genotypes fed adenine compared with casein (n = 4–6 per group). *P < 0.05, **P < 0.01 versus 
casein diet within the same genotype; ‡P < 0.05 versus Cre– on the same diet.
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cortical bone porosity. Furthermore, reducing FGF23 during CKD actually resulted in higher serum BUN 
and phosphorus, as well as more pronounced cardiac hypertrophy. Collectively, these findings demonstrate 
that during CKD, elevated FGF23 has a critical and potentially protective role, including maintaining sys-
temic phosphate for normal cardiac homeostasis.
FGF23 is a central factor in the pathogenesis of  CKD, owing to its impact on endocrine function, 
as well as its associations with morbidity and mortality in this patient population (36, 56). Under nor-
mal physiological circumstances, FGF23 interacts with α-Klotho and FGFR in the kidney to promote 
phosphate excretion and indirectly decrease intestinal phosphate absorption by reducing 1,25D synthesis. 
Initial pathogenic insults during CKD lead to relatively rapid suppression of  α-Klotho, leading to FGF23 
resistance and reduced phosphate clearance (57). Our study herein demonstrated a decrease in renal Klotho 
mRNA expression in adenine-fed mice for 4 weeks, which was similarly suppressed at 8 weeks. Addi-
tionally, serum creatinine and BUN rose between 4 and 8 weeks in the adenine-fed mice compared with 
casein-fed mice, which demonstrates the progressive nature of  this model. In a likely compensatory fash-
ion, iFGF23 levels rose, which led to secondary hyperparathyroidism. Interestingly, perhaps due to the 
competing actions of  FGF23 and PTH, the mice fed adenine showed slight elevations in kidney Cyp27b1. 
Even with normal renal function, elevated FGF23 is known to negatively affect bone homeostasis, as 
underscored by the rachitic phenotype of  patients with autosomal dominant hypophosphatemia (ADHR) 
(21) and X-linked hypophosphatemia (XLH) (58). Recent studies demonstrated that FGF23 neutralization 
using anti-FGF23 antibodies in the Hyp mouse model of  XLH (59) or in XLH patients (60) was able to 
correct serum phosphorus levels to within the normal ranges and improve bone parameters. However, 
with compromised renal function, use of  a neutralizing FGF23 antibody in a rat model of  CKD led to the 
deaths of  the animals (61). It was observed that FGF23 neutralization decreased levels of  serum PTH and 
increased circulating levels of  1,25D (62). This resulted in increased uptake of  calcium and phosphorus 
from the diet, leading to markedly increased serum phosphate.
To circumvent the complete blockade of  FGF23 activity, in previous work we employed the bone-specif-
ic deletion of  FGF23 using the conditional flox-Fgf23 mice (47). Similar to neutralization with anti-FGF23, 
conditional deletion of  Fgf23 in Hyp mice corrected the XLH phenotype. Importantly, when Fgf23 was delet-
ed using Dmp1-Cre for late osteoblasts/early osteocytes, the mice remained modestly responsive to elevated 
phosphorus (47). Indeed, flox-Fgf23/Dmp1-Cre+ mice fed an adenine-containing diet in the current study 
showed increased bone Fgf23 mRNA and serum iFGF23; however, these levels remained far below those 
of  the adenine-fed flox-Fgf23/Dmp1-Cre– mice. In contrast with the aforementioned neutralization studies, 
Table 2. Kidney histological scores
Number of cases
I. Fibrosis Score Casein Cre– Casein Cre+ Adenine Cre– Adenine Cre+
a. None 0 4 4
b. Patchy 1 1 2 1
c. Severe 2 3 3
II. Glomeruli
a. Normal 0 4 5 5 3
b. Drop out 1 1
III. Calcification
a. None 0 4 3 3
b. Minimal 1 1
c. Medulla only 2 2 1
d. Cortex and Medulla 3 1 3
IV. Cell infiltrates
a. None 0 4 4 3 3
b. Present 1 1 2 1
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Figure 3. Cardiac phenotypes with clamped FGF23. (A) 
Echocardiograph images were collected from the mice prior 
to the 8-week time point. Representative long-axis images 
collected in B-mode show the aorta (right) down to the apex 
of the open left ventricle (left). While no gross changes were 
observed between the genotypes at baseline, the flox-Fg-
f23/Dmp1-Cre+ mice fed adenine showed thickened aortic 
walls due to calcification (yellow arrow). Quantification of 
the aortic diameter in the lower panel demonstrated sig-
nificantly lower values in the adenine-fed Cre+ mice. Yellow 
asterisks indicate the apex of the heart; white arrows indi-
cate the aorta to denote similar orientation for each image. 
(B) Representative H&E staining of casein- and adenine-fed 
hearts demonstrates pronounced hypertrophy of the left 
ventricle in the flox-Fgf23/Dmp1-Cre+ mice fed adenine 
compared with the flox-Fgf23/Dmp1-Cre– mice. Lower panel: 
Whereas no differences were observed between genotypes 
on the casein diet, left ventricle wall thickness was higher in 
the adenine-fed flox-Fgf23/Dmp1-Cre+ mice compared with 
both casein-fed mice and adenine-fed flox-Fgf23/Dmp1-Cre– 
mice (n = 4–6 per group). **P < 0.01 versus casein diet within 
the same genotype; ‡‡P < 0.01 versus flox-Fgf23/Dmp1-Cre– 
on the same diet. (C) Wheat germ agglutinin staining of 
the cardiomyocytes demonstrated an increase in cell area, 
a marker of hypertrophy, in the adenine-fed flox-Fgf23/D-
mp1-Cre– mice (lower panel). In the flox-Fgf23/Dmp1-Cre+ 
adenine-fed group, cell area was significantly increased com-
pared with both casein controls as well as the adenine-fed 
flox-Fgf23/Dmp1-Cre– mice (n = 30–40 images per group). 
**P < 0.01 versus casein diet within the same genotype; ‡‡P 
< 0.01 versus Cre– on the same diet.
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serum PTH levels were similar between the adenine-fed Cre– and Cre+ groups. It is possible that even the dra-
matic decrease of  iFGF23 was unable to elicit changes in circulating 1,25D resulting in the secondary rise 
of  PTH. The increase in mortality of  the CKD rats with anti-FGF23 treatment was partially attributed to 
declines in renal function. In agreement with this finding, our study found that after 8 weeks of  diet admin-
istration the flox-Fgf23/Dmp1-Cre+ mice receiving adenine had substantially higher serum BUN compared 
with both casein-fed flox-Fgf23/Dmp1-Cre+ mice and the adenine-fed flox-Fgf23/Dmp1-Cre– mice.
FGF23 has been independently associated with increased risk for all-cause mortality in CKD patients 
(36) through increased incidence of  cardiovascular events (63), the leading cause of  death in this patient 
population (64). Animal models with direct heart injections or intravenous infusion of  high-dose recom-
binant FGF23, as well as Klotho-null mice with elevated serum iFGF23, develop LVH, an index of  heart 
dysfunction and a frequent abnormality found in end-stage renal disease patients (38, 65–67). Addi-
tionally, various animal models of  CKD develop LVH, including adenine diet administration (68), 5/6 
nephrectomy (66), and Col4a3–/– mice (model of  Alport syndrome; ref. 69); however, these are not always 
consistent, also relying upon the genetic background of  the mice. In our hands, the hypertrophy of  the 
adenine diet in the flox-Fgf23/Dmp1-Cre– mice was modest over the 8-week time course. Interestingly, 
the adenine-fed flox-Fgf23/Dmp1-Cre+ mice showed significant LVH at 8 weeks of  diet administration by 
histology. This supports the concept that development of  LVH in CKD is multifactorial and not solely 
dependent on markedly elevated serum iFGF23. Indeed, even with global ablation of  FGF23, LVH can 
be induced through pressure overload (70). Serum phosphorus was increased in all of  the adenine-fed 
mice; however, the levels were highest in the flox-Fgf23/Dmp1-Cre+ mice. In our studies, echocardiographs 
also showed a decrease in aortic width in the adenine-fed flox-Fgf23/Dmp1-Cre+ mice from mineral accu-
mulation. In the previous report of  CKD rats treated with anti-FGF23 neutralizing antibody, the authors 
observed increased vascular calcifications compared with the vehicle-treated CKD rats, which was also 
attributed to the elevated serum phosphorus. In contrast to our results, however, heart weight and LVH 
were unchanged between the vehicle- and anti-FGF23–treated CKD rats (61). These differences could 
potentially be explained by the differences in duration of  hyperphosphatemia and extent of  vascular 
calcifications, rodent-specific local factors, or the endocrine profiles of  the 2 models. Exposure to high 
serum phosphorus has been shown to cause dedifferentiation of  the vascular smooth muscle cells into 
osteoblast-like cells that inappropriately deposit matrix material (71). The arterial stiffness caused by this 
mineralized material increases the demands on the heart, resulting in hypertrophy (72). Additionally, in 
vitro experiments have demonstrated that treatment of  cardiomyocytes with exogenous phosphate can 
directly induce hypertrophic signals (73). Reduced 1,25D and vitamin D receptor signaling within cardio-
myocytes has also been shown to induce hypertrophy (74, 75). Although the cardiac hypertrophy in the 
adenine-fed flox-Fgf23/Dmp1-Cre– mice was modest, it is possible that the change in 1,25D from iFGF23 
reduction was not sufficient to block cardiomyocyte hypertrophy in the adenine-fed flox-Fgf23/Dmp1-Cre+ 
mice. Additionally, high serum PTH has been associated with cardiovascular events and it was shown that 
treatment with PTH for 2 weeks after transverse aortic banding decreased heart function and increased 
heart size (76). Thus, it is possible that the high serum PTH in the adenine-fed flox-Fgf23/Dmp1-Cre+ mice 
could contribute to the development of  LVH. Finally, Slavic et al. have shown that after transverse aortic 
constriction, heart tissue and cardiomyocytes can express FGF23 (70). This may act in an autocrine or 
paracrine manner within the heart by signaling through FGFR4 and inducing hypertrophy through the 
PLC-γ/NFAT/calcineurin pathway (66). It is therefore possible that there is a compensatory upregulation 
Table 3. Echocardiography parameters
Casein Cre– Casein Cre+ Adenine Cre– Adenine Cre+
LVID/s 2.87 + 0.08 2.89 + 0.11 2.89 +1.8 1.74 + 0.38A,B
LVPW/s 0.83 + 0.03 0.86 + 0.04 0.89 + 0.04 1.25 + 0.11A,B
EF% 48.8 + 2.2 50.9 + 2.9 47.2 + 4.7 73.6 + 12C
FS% 24.2 + 1.3 25.6 + 1.7 23.6 + 2.9 45.6 + 10.5C,D
LVID/s, left ventricle inner diameter in systole; LVPW/s, left ventricle posterior wall in systole; EF, ejection fraction; FS, fractional shortening. Data 
presented as mean + SD. n = 4–6/group. AP < 0.01 vs. casein diet, same genotype. BP < 0.01, CP < 0.05 vs. Cre–, same diet. DP < 0.05 vs. casein diet, same 
genotype.
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of  FGF23 within cardiomyocytes in the adenine-fed flox-Fgf23/Dmp1-Cre+ mice. Future studies will be 
needed to assess cardiomyocyte signaling events during CKD utilizing heart conditional deletion of  Fgf23.
Bone homeostasis in CKD is also severely affected; a combination of  increased cortical porosity and 
reduced bone quality in CKD patients increases fracture risk, independently increasing morbidity and mor-
tality (77–80). In this study, we found that the adenine-fed mice, along with the alterations in mineral 
homeostasis, incurred elevated cortical porosity compared with the casein-fed mice. Unlike the FGF23 
neutralization studies, the bones from mice fed the adenine diet showed no improvement with osteoblast/
osteocyte deletion of  FGF23. Chronic PTH in CKD elicits high bone turnover that was alleviated with 
anti-FGF23 treatment, likely due to reduced PTH (61). The improved bone in the rat CKD studies was 
likely due to the observation that neutralization of  FGF23 reduced serum PTH, whereas PTH was not dif-
ferent between the adenine-fed flox-Fgf23/Dmp1-Cre– and flox-Fgf23/Dmp1-Cre+ groups herein. We hypoth-
esize that this is the reason that cortical porosity was not improved despite FGF23 reduction.
In summary, we found that FGF23 is protective during CKD by acting to maintain serum phosphate in 
the normal ranges. Inhibition of  FGF23 during kidney disease onset results in elevated serum phosphorus, 
more severe renal disease, and cardiac hypertrophy. It is likely that other factors in addition to serum phos-
phate increase FGF23 during CKD; thus, it will be necessary to determine the balance of  circulating FGF23 
concentrations that permit adequate phosphate handling but potentially limit detrimental, off-target events.
Methods
Animal studies. Flox-Fgf23 mice were derived as described previously (47).
Conditional deletion of  the flox-Fgf23 allele. Heterozygous flox-Fgf23 (Fgf23fl/+) mice were bred to generate 
Fgf23fl/fl/Cre+/– mice using the 8-kb dentin matrix protein 1 (Dmp1)-Cre (48) transgenic mouse line. All gen-
otype analyses were performed as previously described (47).
Rodent diets. Mice were weaned at 3 weeks of age. Beginning at 8 weeks of age, mice were provided a control 
casein-base rodent diet (0.9% phosphate and 0.6% calcium, TD.150303 Envigo). To induce CKD, littermates 
were placed on a 0.2% adenine–containing diet supplemented into the casein base (TD.160020; Envigo), until 
sacrifice after 4 and 8 weeks on diets; group sizes were 4–7 animals. Diets and water were provided ad libitum.
Cardiac analysis. Three days prior to harvest, experimental mice underwent echocardiography imag-
ing. Mice were anesthetized with isoflurane and placed on a warming mat with continuous monitoring. 
Transthoracic ECHO images were obtained using a VisualSonics 2100 ultrasound machine for small-animal 
imaging and MS400 transducer (Fujifilm VisualSonics, Inc.). A 40-MHz hand-held mechanical transducer 
containing both imaging (B-mode) and Doppler transducers with a frame rate of  34 Hz was used to image 
the heart in multiple views and measure aortic diameter. M-mode–captured transaxial images of  the left ven-
tricle were used to determine left ventricle width measurements and calculate ejection fraction and fractional 
shortening. At necropsy, hearts were fixed in 4% paraformaldehyde (PFA). Heart volume and myocardial 
calcification were evaluated using iodine potassium iodide (I2KI) tissue staining and μCT imaging. Hearts 
were placed in 1 ml of  Lugol’s solution, aqueous potassium iodide plus iodine (Sigma Aldrich, L6146) 
for 24 hours, and then returned to 1 ml of  neutral buffered formalin. I2KI-stained hearts were dabbed dry 
to remove residual solution, and then scanned (Skyscan, 1172) at a resolution of  9 μm while wrapped in 
Parafilm to reduce sample dehydration. A threshold was applied to the volume of  interest to define myocar-
dium (VOI 20–75) and myocardial calcification (VOI 75–255). Graphic renderings of  hearts were generated 
(CTVox, Bruker) with myocardium defined as red and myocardium calcification as white. All hearts were 
subsequently paraffin embedded and transverse sections at 7-μm thickness were stained with H&E. Images 
were stitched on a Leica microscope at ×5 magnification. ImageJ (NIH) was used to determine left ventric-
ular wall thickness by taking 7 measurements of  the left ventricle free wall from each sample. Sections were 
deparaffinized and stained with Alexa Fluor 488–conjugated wheat germ agglutinin (Life Technologies). 
Fluorescence images were captured on a Leica microscope at ×20 magnification with 8–10 left ventricle free 
wall images per sample. ImageJ was used to measure the cell area from 50–100 cells per image.
Kidney histology. At necropsy, kidneys were perfused with 0.9% saline and 4% PFA for fixation. Par-
affin-embedded 7-μM sections were stained with H&E, Masson’s trichrome for fibrosis, and von Kossa 
with methyl green counterstain for imaging mineral deposition. Histology scores were semiquantitatively 
assessed in 3 sections per specimen in a blinded manner by an experienced nephrologist. Images were 
captured on a Leica microscope at ×2.5 and ×10 magnifications. Analyses were done by comparing 
those without and with any calcification.
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Serum biochemistries. Blood samples were collected from mice for interim analyses by facial vein bleed 
and at the time of  euthanasia by cardiac puncture. Routine serum biochemistries were determined in the 
Laboratory of  the Clinical and Translational Sciences Institute (CTSI) of  the Indiana University School of  
Medicine using an automated COBAS MIRA Plus Chemistry Analyzer (Roche Diagnostics). Serum total 
iron measures ferric iron bound to transferrin, which was processed and analyzed according to the man-
ufacturer’s protocol (Randox Laboratories). Serum iFGF23 and intact PTH concentrations were assessed 
using commercial ELISAs (Quidel, Inc.).
μCT. Femurs were removed after necropsy and fixed in 4% PFA. Bones were scanned using μCT (Sky-
scan 1172) at 6-μm micron resolution to assess trabecular and cortical bone morphometry. A defined region 
of  interest in the distal femur (~0.5 mm from the growth plate and encompassing 1 mm of  slices in the 
proximal direction) was used to determine trabecular bone volume/total volume (BV/TV). A single cor-
tical bone slice (2 mm proximal to the most proximal slice defined for trabecular analysis) was analyzed 
for cortical porosity by isolating the cortical shell and determining void space (100 – [BV/TV]). The termi-
nology and units used are those recommended by the American Society for Bone and Mineral Research 
Guidelines for assessment of  bone microstructure in rodents using μCT (49).
RNA preparation and quantitative RT-PCR (qPCR). Kidneys and bones were harvested and homoge-
nized in 1 ml of  TRIzol reagent (Invitrogen) according to the manufacturer’s protocol using a Bullet 
Blender (Next Advance, Inc.), then further purified using the RNeasy Kit (Qiagen). RNA samples were 
tested with intron-spanning primers specific for Fgf23 (bone), Cyp27b1, Col1a1, Tnfa, Crp, Il6, Runx2, 
and Klotho (kidney) mRNAs; mouse β-actin or Gapdh was used as an internal control by RT-qPCR. The 
qPCR primers and probes were purchased as pre-optimized reagents (Applied Biosystems/Life Tech-
nologies, Inc.) and the TaqMan One-Step RT-PCR kit was used to perform qPCR. PCR conditions for 
all experiments were 30 minutes 48°C, 10 minutes 95°C, followed by 40 cycles of  15 seconds 95°C and 
1 minute 60°C. The data were collected and analyzed by a StepOne Plus system (Applied Biosystems/
Life Technologies, Inc.). The expression levels of  mRNAs were calculated relative to appropriate litter-
mate genotype controls, and the 2–ΔΔCT method described by Livak was used to analyze the data (50).
Statistics. Statistical analysis of  the in vivo and in vitro data was performed by 2-way ANOVA followed 
by Tukey’s post hoc test. Statistical significance for all tests was set at P < 0.05. Data are presented as box-
and-whisker plots, where the middle line represents the median of  the data, upper and lower quartiles are 
within the boxes, and the whiskers are the minimum and maximum.
Study approval. Animal studies were approved by and performed according to the Institutional Animal 
Care and Use Committee (IACUC) of  Indiana University, and comply with the NIH guidelines for the use 
of  animals in research.
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